• What positive psychology does is reverse the basic questions that have animated clinical psychology from the beginning.

    FORBES: Atlantic Philanthropies and Charles F. Feeney: How Wealth-in-Action Redeems Us All

  • They're also asking Merck and Schering-Plough some arcane questions about how the failed clinical trial, called ENHANCE, was constructed.

    FORBES: Magazine Article

  • It was an analysis of published clinical trials that raised the first big questions about drug-coated stents causing heart attacks in rare cases.

    FORBES: Open-Source Drug Safety?

  • They're also asking Merck (nyse: MRK - news - people ) and Schering-Plough (nyse: SGP - news - people ) some arcane questions about how the failed clinical trial, called ENHANCE, was constructed.

    FORBES: Vytorin's Missing Fail-Safes

  • The large clinical trials being conducted by GlaxoSmithKline may not answer questions about whether Avandia causes heart attacks or which patients are put at risk by the drug.

    FORBES: Unsafe At The FDA

  • However, concerns over its impact on LDL and HDL (as well as anemia, neutrophil suppression, and liver enzymes elevations) lingered and questions regarding whether these laboratory measures would translate into clinical events were raised.

    FORBES: Pfizer's Key Drug Walks A Tightrope

  • It added: "We do not believe there are any clinical concerns regarding the care of patients, but rather there are questions that need answering about how the trust reports information about their care for administrative and financial purposes".

    BBC: Royal Bolton Hospital

  • Kroll has some questions about whether Quintiles invests in the same drugs for which it runs clinical trials and whether that represents a conflict of interest.

    FORBES: More On Quintiles' Pharmaceutical Investments

  • These are all questions that NIAID together with our partners plans to address through continued basic and clinical research.

    WHITEHOUSE: HIV Vaccine Awareness Day, 2011

  • Michael Phillips, a board member and clinical assistant professor at New York University School of Medicine, asked a series of skeptical questions.

    WSJ: City Drinks Plan Questioned

  • The long delay in getting the ENHANCE out is likely to raise questions about how much control drug companies should have over the conduct of their clinical trials.

    FORBES: Vytorin Study Shows No Benefit

  • The long delay to getting the Enhance study out is likely to raise questions about how much control drug companies should have over the conduct of their clinical trials.

    FORBES: Magazine Article

  • On the other end of the phone line, relaying the clinical condition of the patient was someone who provided the most germane information and anticipated my questions before I posed them.

    FORBES: Sometimes The Best Medical Care Is Provided By Those Who Aren't M.D.s

  • Now, Innis and CORE are looking to help start up a small clinical trial at New York's Cabrini Medical Center to help answer some of these questions, while at the same time shoring up a still-unproven technology.

    FORBES: Race, Medicine: An Explosive Mix

  • Although it had been the subject of earlier questions, serious criticism emerged with the publication in 2009 of the TREAT trial, which found no clinical benefit for the drug in patients with chronic kidney disease.

    FORBES: Amgen Pleads Guilty To Misbranding Anemia Drug Aranesp

  • Venook will be heading up a clinical trial with Erbitux and chemotherapy in previously untreated patients for Bristol and ImClone, and that could help further answer questions about the drug's effectiveness.

    FORBES: Puncturing The ImClone Hype

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定